Starting off 2019 with a bang, Bristol-Myers Squibb has announced its intention to acquire fellow drugmaker Celgene as part of an agreement which, valued at approximately $74 billion, would be the largest pharmaceutical deal ever, eclipsing Bayer and Monsanto’s $63 billion merger in 2016.
Revealing the move, BMS said the deal would seek to create “a leading focused specialty biopharma company well positioned to address the needs of patients with cancer, inflammatory and immunologic disease and cardiovascular disease”.
